Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Product information and disease descriptionProduct descriptionProduct information

Product comparison

18 evidence topics · 19 sources

Mevrometostat plus enzalutamide: MEVPRO-1 and MEVPRO-2 phase 3 designs

“MEVPRO-1 ( NCT06551324 ) is an open-label, phase III trial which will evaluate mevrometostat plus enzalutamide versus physician’s choice of either enzalutamide or docetaxel in patients with mCRPC who have progressed following ≥12 weeks of treatment with abiraterone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Randomization will be stratified by previous docetaxel in the metastatic castration-sensitive prostate cancer (mCSPC) setting, physician’s choice of comparator (prespecified prior to randomization and will remain consistent throughout the study), and presence of hepatic metastases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“MEVPRO-2 ( NCT06629779 ) is a double-blind, placebo-controlled, phase III trial that will evaluate mevrometostat plus enzalutamide versus enzalutamide alone in adult patients with mCRPC who are treatment-naïve” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The primary efficacy endpoint for both MEVPRO-1 and MEVPRO-2 is rPFS per RECIST 1.1 (soft tissue) and PCWG3 (bone) assessed by BICR. OS (alpha protected) is a key secondary endpoint in both studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“There will be no interim analysis for the primary endpoint (rPFS).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Company benchmark comparison: landmark rPFS and safety versus mevrometostat after abiraterone
RegimenMedian follow-upMonth 3 rPFSMonth 4 rPFSMonth 5 rPFSGrade 3 or higher TRAEsDose reductions / discontinuations
Mevrometostat 875 mg twice daily fed plus enzalutamide (n=14)“9.2” months“92%”“92%”“84%”“36%”“7% / 7%”
Mevrometostat 1250 mg twice daily fasted plus enzalutamide (n=41)“11.7” months“92%”“86%”“80%”“49%”“37% / 2%”
Enzalutamide monotherapy (n=40)“9.0” months“78%”“70%”“60%”“23%”“8% / 5%”
Rinzimetostat 400 mg once daily plus darolutamide (n=18)“4.9” months“93%”“84%”“84%”“6%”“None / 6%”
Company benchmark comparison: serious adverse events and dose modifications versus mevrometostat
MeasureMevrometostat 875 mg twice daily fed plus enzalutamide (n=14)Mevrometostat 1250 mg twice daily fasted plus enzalutamide (n=41)Rinzimetostat 400 mg once daily plus darolutamide (n=18)
Grade 3 or higher TRAEs“36%”“49%”“6%”
Serious TRAEs“21%”“24%”“None”
Dose reductions“7%”“37%”“None”
Treatment discontinuations“7%”“2%”“6%”